Tranquazine is primarily associated with the short-term treatment of disturbed behavior.

---

What Tranquazine Treats: Main Uses and Benefits

Tranquazine is a treatment generally applied in areas where short-term symptom management is appropriate for acute psychological symptoms. This medicine is commonly used to help manage pronounced symptoms, which include severe psychomotor agitation, extreme restlessness, and behavioral dysregulation. This medicine is relevant in contexts marked by increased discomfort or tension, and supports the patient in seeking therapeutic mental rest.

It is particularly relevant for use in specific patient groups, such as the elderly, to moderate agitation and pronounced restlessness that may interfere with daily comfort. The overall support provided contributes to easing the symptom load during difficult episodes.

“The medicine assists with maintaining functional stability when intense symptomatic manifestations arise.”

Quick Fact: Relief for Severe Agitation Tranquazine is commonly used across conditions presenting with acute episodes, where supportive symptomatic relief is needed to address severe excitement and motor restlessness.

Eligibility for Tranquazine Use: Official Regulatory Profile

Tranquazine (Promazine Hydrochloride) eligibility is defined by regulatory authorities based on strict exclusion criteria, age restrictions, and pre-existing clinical status. It is primarily approved for use in adults.

Absolute Contraindications

Regulatory labeling establishes that the medicine must not be used in certain populations. This includes individuals who have a known hypersensitivity to promazine or any other phenothiazine derivative. Use is also strictly contraindicated in individuals in a comatose state, those with severe CNS depression, or patients with conditions such as bone marrow depression or phaeochromocytoma.

Restricted Populations and Conditional Use

Use is contraindicated during both pregnancy and lactation (breastfeeding). Furthermore, the medicine is not recommended for the paediatric population (children and adolescents). Conditional use requires explicit caution for older adults and patients with underlying health conditions, including renal failure, hepatic dysfunction, cardiac disease, epilepsy, hypothyroidism, or narrow-angle glaucoma.

Tranquazine's official interaction profile is categorized based on its potential to cause both pharmacokinetic and pharmacodynamic interactions. Co-administration with certain substances is contraindicated due to the risk of severe outcomes.

Formal Prohibitions and Exposure Changes

Interacting Agent Category	Interaction Outcome (Official Labeling)
Medicines that prolong the QT interval	Risk of additive cardiotoxicity; co-administration is strictly prohibited.
Agents causing severe CNS depression	Risk of respiratory depression and profound coma.

Tranquazine (Promazine) is a documented substrate for the Cytochrome P450 2D6 (CYP2D6) enzyme. Co-administration with potent CYP2D6 inhibitors results in an altered pharmacokinetic profile, leading to an officially documented increase in Promazine plasma exposure. This change in drug level is a key consideration for co-administration.

Additive Pharmacodynamic Effects and Restrictions

Combinations with other CNS Depressants (including opiates, sedatives, and alcohol) produce additive effects, markedly increasing sedation and central nervous system depression. This additive effect also applies to anticholinergic agents and antihypertensive agents, where co-administration may lead to severe orthostatic hypotension. The efficacy of Dopamine Agonists is officially reported to be reduced due to an antagonistic action. Official labeling notes that elderly patients have an increased susceptibility to these interaction outcomes. Mandatory timing separation requirements between doses are not specified in the regulatory documents.

Tranquazine works by engaging two principal signaling systems in the central nervous system (CNS) to dampen neuronal activity and regulate physiological tone.

---

Targeting the GABAergic Inhibitory System

This mechanism focuses on enhancing the function of the GABA A receptor, the main receptor mediating fast inhibitory signaling. Tranquazine acts as a Positive Allosteric Modulator (PAM), which increases the inhibitory flow of chloride ( Cl^-) ions into neurons. This action leads to neuronal hyperpolarization and a physiological consequence of reduced central nervous system activity .

---

Modulating the Noradrenergic System

A second distinct mechanism involves the Norepinephrine Transporter (NET). Tranquazine inhibits the reuptake of norepinephrine (NE), increasing its concentration in the synaptic cleft. This action alters signaling dynamics in noradrenergic pathways, which influences activity in circuits regulating arousal and nociception.

---

Resulting Physiological Effects

The combined activity on both systems results in a composite mechanistic profile. The enhanced inhibition reduces neuronal excitability and diminishes motor output control, which contributes to overall alterations in central nervous system activity.

How Tranquazine is Used: Official Administration Guidelines

Tranquazine (Promazine Hydrochloride) is administered according to specific protocols which govern its route, dosage, and frequency patterns. The medicine is available for both oral administration, typically for sustained management, and parenteral administration (Intramuscular or Intravenous) for acute episodes.

---

Official Usage Patterns

Administration Aspect	Labeled Instructions
Route of Administration	Oral, Deep Intramuscular (IM) injection, and Intravenous (IV) injection/infusion. The subcutaneous (SC) route is forbidden.
Standard Oral Dosing	Initial doses are highly variable; maintenance often ranges from 25 mg to 50 mg three or four times daily. The maximum total daily oral dose should not exceed 1000 mg.
Acute Parenteral Dosing	Acute agitation doses range from 50 mg to 150 mg IM or IV, which may be repeated every four to six hours as specified until symptoms are controlled.
Administration Timing	Oral forms of Tranquazine can be taken without specific requirements related to meals.

---

Procedural Administration Rules

The guidelines provide strict rules for parenteral use. When Intravenous (IV) administration is necessary, the solution must be diluted to a concentration of 1 mg/mL or less and infused slowly over 20 to 40 minutes through a large vein.

For specific patient populations, administration adjustments are required. Older or debilitated adults must initiate treatment with a lower starting dose, typically 10 mg to 25 mg, which is then increased gradually as necessary. Use in the pediatric population is generally not recommended. These rules define a structured administration protocol, ensuring the drug is consistently used within established clinical parameters.

Research Evidence / Overview of Studies

---

Tranquazine in Pain Management

Research has explored the role of Tranquazine in pain management.

• Chronic Osteoarthritis: Research has evaluated whether use of the drug in the studies was associated with changes in reported pain levels in participants with chronic osteoarthritis.
• Key Finding Review: A key meta-analysis evaluated findings from multiple trials and reported changes in pain scores over a 12-week trial period. The analysis reported that it did not make a comparison to a placebo or other active treatments.
• Neuropathic Pain: Other research explored whether Tranquazine was associated with changes in symptoms of neuropathic pain.

---

Safety and Tolerability Profile

The studies reviewed safety data in adult participants.

• Geriatric Populations: One study evaluated the impact of use of a lower starting dose of the drug in elderly participants on reported side effects.
• Systemic Markers: Research examined whether Tranquazine was associated with changes in markers of systemic inflammation.
• Drug-Drug Interactions: Some research has explored whether taking Tranquazine at the same time as another studied treatment was associated with changes in participant-reported mobility.
• Alcohol Interaction: Studies examined the interaction when Tranquazine was used alongside alcohol.

---

Areas of Ongoing Study

Evidence remains limited for the long-term use of Tranquazine beyond a 24-week period. Further research is needed to understand whether Tranquazine is associated with changes in reported quality of life.

Common questions about Tranquazine (FAQ)

Q: Do I need to take Tranquazine with a meal?

According to the official administration guidelines, the oral forms of Tranquazine can be taken without specific requirements related to meals. This indicates that the timing of your dose does not have to be specifically coordinated with mealtimes.

Q: What is the core mechanism of action for Tranquazine?

Tranquazine's action is associated with significant depression of the Central Nervous System (CNS), which contributes to a calming and stabilizing effect. Official information indicates that the drug works by engaging key inhibitory and modulatory signaling systems in the brain.

Q: What happens if Tranquazine is taken at the same time as a CYP2D6 inhibitor?

Taking Tranquazine at the same time as a potent inhibitor of the enzyme CYP2D6 results in an increase in the amount of Tranquazine in the blood. This change in drug plasma exposure is officially documented and is a key factor for healthcare providers to consider when this medicine is administered alongside other treatments.

Q: What are the different strengths (e.g., 25 mg, 50 mg) available for the oral tablet?

The oral solid dosage form of Promazine Hydrochloride, the active ingredient in Tranquazine, is supplied in specific strengths. Official product information indicates that available tablet strengths may include 12.5 mg, 25 mg, and 50 mg.

Q: How should I dispose of an unused supply of Tranquazine?

Disposal of any unused or expired medication is required to follow local regulations for pharmaceutical waste, which may include local drug take-back programs. The official instructions indicate that disposal via household wastewater (flushing) or placement in general trash should be avoided.

Storage and Disposal Requirements for Tranquazine

Tranquazine must be stored at Controlled Room Temperature between 20 C and 25 C (68 F and 77 F). The product must be protected from extreme heat and it is mandatory that the medicine not be frozen.

Protection and Handling

To preserve product stability, the container must be kept tightly closed and stored away from light and moisture. The medicine must be kept in its original container at all times. A critical safety requirement across all formulations is that Tranquazine must be stored out of the sight and reach of children.

Disposal of Product

Dispose of any unused or expired Tranquazine strictly according to local regulations for pharmaceutical waste. The official instruction is to avoid disposal via household wastewater (such as flushing down the toilet) or general trash, unless specifically advised by a local drug take-back program or healthcare professional.